{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:49:34Z","timestamp":1789663774107,"version":"4.0.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir. J. Med. Sci."],"published-print":{"date-parts":[[1999,4]]},"DOI":"10.1007\/bf02946481","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T08:33:41Z","timestamp":1221208421000},"page":"124-126","source":"Crossref","is-referenced-by-count":16,"title":["Are elevated levels of the tumour marker CA19-9 of any clinical significance? \u2014 An evaluation"],"prefix":"10.1007","volume":"168","author":[{"given":"R.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"O\u2019Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F.","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02946481_CR1","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/1097-0142(19871115)60:10<2428::AID-CNCR2820601013>3.0.CO;2-O","volume":"60","author":"E. Beretta","year":"1987","unstructured":"Beretta, E., Malesci, A., Zerbi, A. et al. Serum CA19-9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 2424\u201331.","journal-title":"Cancer"},{"key":"BF02946481_CR2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1988.6.3.462","volume":"6","author":"J. Glen","year":"1988","unstructured":"Glen, J., Steinberg, W. M., Kartman, S. et al. Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J. Clin. Oncol. 1988; 6: 462\u20138.","journal-title":"J. Clin. Oncol."},{"key":"BF02946481_CR3","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V","volume":"60","author":"B. Gudjonson","year":"1987","unstructured":"Gudjonson, B. Cancer of the pancreas; 50 years of surgery. Cancer 1987; 60: 2284\u20132303. 4. Steinberg, W. The clinical utility of the CA19-9 tumour associated antigen. Am. J. Gastroenterol. 1990; 85: 350\u2013355.","journal-title":"Cancer"},{"key":"BF02946481_CR4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ijc.2910330310","volume":"33","author":"R. E. Ritts","year":"1984","unstructured":"Ritts, R. E., Delvillano, B. C., Go, V. et al. Initial clinical evaluation of an immunoradiometric assay for CA19-9 using NCI serum bank. International J. Cancer 1984; 33: 339\u201345.","journal-title":"International J. Cancer"},{"key":"BF02946481_CR5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/jcp.37.2.218","volume":"37","author":"H. Jalanko","year":"1984","unstructured":"Jalanko, H., Kuusela, P., Roberts, P. et al. Comparison of a new tumour marker CA19-9 with alpha-feto protein and CEA in patients with upper gastrointestinal diseases. J. Clin. Pathol. 1984; 37: 218\u201322.","journal-title":"J. Clin. Pathol."},{"key":"BF02946481_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000199271","volume":"33","author":"A. Andriulla","year":"1986","unstructured":"Andriulla, A., Gindro, T., Piantiso, P. et al. Prospective evaluation of the diagnostic efficacy of CA19-9 as a marker for gastrointestinal cancer. Digestion 1986; 33: 26\u201333.","journal-title":"Digestion"},{"key":"BF02946481_CR7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJM199202133260706","volume":"326","author":"A. Warshaw","year":"1992","unstructured":"Warshaw, A., Castillo, C. F. Pancreatic Carcinoma. N. Engl. J. Med. 1992; 326: 455\u2013462.","journal-title":"N. Engl. J. Med."},{"key":"BF02946481_CR8","first-page":"5489","volume":"43","author":"J. Magnani","year":"1983","unstructured":"Magnani, J., Steplewski, Z., Koprowski, H., Ginsburg, V. Identification of the gastrointestinal and pancreatic associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983; 43: 5489\u20135492.","journal-title":"Cancer Res."},{"key":"BF02946481_CR9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00006676-199201000-00011","volume":"7","author":"C. Niederau","year":"1992","unstructured":"Niederau, C., Grendell, J. Diagnosis of pancreatic carcinoma. Imaging techniques and tumour markers. Pancreas 1992; 7: 66\u201386.","journal-title":"Pancreas"},{"key":"BF02946481_CR10","first-page":"833","volume":"4","author":"J. M. Rhodes","year":"1990","unstructured":"Rhodes, J. M., Ching, C. Serum diagnostic tests for pancreatic cancer. Clin. Gastroenterol. 1990; 4: 833\u201352.","journal-title":"Clin. Gastroenterol."},{"key":"BF02946481_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00000658-198311000-00008","volume":"198","author":"A. Andron-Sandberg","year":"1983","unstructured":"Andron-Sandberg, A., Ihse, I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann. Surg. 1983; 198: 605\u2013610.","journal-title":"Ann. Surg."},{"key":"BF02946481_CR12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/bjc.1994.93","volume":"69","author":"J. Lundin","year":"1994","unstructured":"Lundin, J., Roberts, P. J., Kuusela, P., Haghind, C. The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. Br. J. Cancer 1994; 69: 515\u2013519.","journal-title":"Br. J. Cancer"}],"container-title":["Irish Journal of Medical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02946481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02946481\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02946481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T20:17:11Z","timestamp":1558469831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02946481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["BF02946481"],"URL":"https:\/\/doi.org\/10.1007\/bf02946481","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}